EGFR and breast carcinoma: In conclusion, we investigated the pivotal role of PI4KIIα in the regulation of EGFR protein levels, and our functional studies indicate that PI4KIIα represents a promising therapeutic target that could be used in combination with existing EGFR treatments used in breast cancer and NSCLC therapy.